Researchers said that while finding an effective vaccine and getting it to the market will likely take more than a year, repurposing drugs already approved could be a much faster way to treat and prevent COVID-19 infection, CNBC reported.
The researchers said physicians will likely need to use a combination of several different drugs and suggested scientists trial drugs that target parts of human cells that the COVID-19 virus attaches itself to.
“Any drug to treat COVID-19 will need to focus on the three key stages of infection: preventing the virus entering our cells in the first place, stopping it replicating if it gets inside the cells, and reducing the damage that occurs to our tissues, in this case, the lungs and heart,” Anthony Davenport, one of the study’s researchers, told CNBC.
The researchers said Gilead’s drug, remdesivir, is a “promising candidate,” and stressed the importance of moving quickly to identify other potential drugs, according to CNBC.
Read the full article here.
More articles on pharmacy:
CVS’ goal of opening 1,500 HealthHubs on track despite pandemic
FDA clarifies relaxed compounding rules for pharmacies
Gilead gets FDA emergency use authorization for remdesivir
